Eribulin Mesylate Demonstrates Activity in Taxane-Sensitive Non-Small-Cell Lung Cancer

Share this content:

(ChemotherapyAdvisor) – The halichondrin B analog eribulin mesylate was found to be well tolerated and demonstrated activity in patients with non–small-cell lung cancer sensitive to taxane, according to results of a open-label Phase 2 study published in the March 2012 issue of the Journal of Thoracic Oncology.

The study included 66 patients previously treated with up to two prior platinum- and taxane-based regimens for metastatic disease or as adjuvant therapy. Patients were stratified by taxane-sensitivity: those taxane-sensitive had progression >90 days after taxane, while those taxane-resistant had progression ≤90 days after taxane. Eribulin 1.4mg/m2 was administered as an IV infusions days 1 and 8 every 21 days. Primary end point was objective response rate; secondary end points included progression-free survival (PFS) and overall survival (OS).

Overall objective response rate was 5%, and median duration of response was 7.8 months. In patients who were taxane-sensitive, 3 of 45 patients (7%) achieved a partial response and 11 (24%) achieved stable disease for at least three months. In the taxane-resistant arm, no patients achieved a partial response and 4 of 21 (19%) achieved stable disease for at least three months.

Median PFS was 2.9 months in the taxane-sensitive arm and 1.2 months in the taxane-resistant arm; median OS was 12.6 and 8.9 months, respectively. Toxicities were primarily hematologic and two patients developed grade 3 neuropathy.

Eribulin mesylate is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.


Prescribing Information

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs